Thanks for visiting Scientific Computing World.

You're trying to access an editorial feature that is only available to logged in, registered users of Scientific Computing World. Registering is completely free, so why not sign up with us?

By registering, as well as being able to browse all content on the site without further interruption, you'll also have the option to receive our magazine (multiple times a year) and our email newsletters.

Transforming a clinical lab into a COVID-19 ready lab

Share this on social media:

L7 Informatics and Contamination Source Identification (CSI) have announced a partnership to accelerate the implementation of testing for COVID-19 patient screening.

L7 Informatics, a provider of in data and workflow management, and Contamination Source Identification (CSI) are deploying 'ready to go' COVID-19 workflows based on the CDC testing protocol for testing laboratories supporting coronavirus patient screening.  

Vasu Rangadass, CEO of L7comments: ‘We are pleased to have CSI as our partner in developing COVID-19 testing workflows using the ESP platform. As testing reagent shortages are addressed, laboratory capacity will become the limitation in diagnosing COVID-19. We decided to make these workflows available for COVID-19 diagnosis to ensure broad access to these critically important tests.’

Through a partnership with CSI, L7 has developed and qualified an integrated workflow for performing COVID-19 diagnostic testing based on the CDC recommended protocols. L7's Enterprise Science Platform (ESP) is used to digitise COVID-19 testing procedures, connect testing processes with laboratory instruments and software systems, and integrate data management and reporting.  ESP's highly flexible and configurable process engine supports standardising laboratory processes while providing flexibility to local laboratories to rapidly adapt protocols without the need of software programming.

Justin Wright, Co-Founder of CSI said: ‘The rapid onset of the COVID-19 pandemic has sparked a need for swift action from diagnostic labs across the country. At CSI, we sought to respond to this need and rapidly developed a Next Generation Sequencing (NGS) assay focused on SARS-CoV-2 detection, in addition to implementing systems in our lab to execute the CDC's COVID-19 rt-qPCR protocol. This rapid response would not have been possible without the dedicated efforts from our partners at L7, who have worked with us in real-time to develop a comprehensive LIMS platform that permits efficient and accurate processing of our critical samples.’

L7 Informatics will host a webinar on Thursday, April 16th at 2:00 pm EST to describe the development and deployment of COVID-19 testing workflows at CSI. You can sign up for this webinar using the link below.

Company: